|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.45 USD | -2.24% |
|
-4.44% | +30.58% |
| 05-09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
| 05-08 | Revolution Medicines Q1 Net Loss Narrows | MT |
Revolution Medicines, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 0.742 million compared to USD 15.33 million a year ago. Net loss was USD 161.54 million compared to USD 56.51 million a year ago.
Basic loss per share from continuing operations was USD 1.14 compared to USD 0.63 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +30.58% | 6.53B | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
REVOLUTION MEDICINES, INC. 